【远大医药(00512.HK)全球创新放射性核素偶联药物 TLX591 加入国际多中心 III 期临床试验的申请已获中国药监局受理】远大医药(00512.HK)公布,该集团用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)加入国际多中心 III 期临床试验的申请,近日已获得中华人民共和国国家药品监督管理局正式受理,这是集团在核药抗肿瘤诊疗领域的重要研发进展。该集团高度重视核药产业全球化发展战略,积极推进创新核药产品的全球化开发及注册进程,并将持续深化集团核药产品管线的全球化拓展。

金融界
07 May
远大医药(00512.HK)公布,该集团用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)加入国际多中心 III 期临床试验的申请,近日已获得中华人民共和国国家药品监督管理局正式受理,这是集团在核药抗肿瘤诊疗领域的重要研发进展。该集团高度重视核药产业全球化发展战略,积极推进创新核药产品的全球化开发及注册进程,并将持续深化集团核药产品管线的全球化拓展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10